Early safety check for new MS drug candidate begins
NCT ID NCT07225517
First seen Nov 06, 2025 · Last updated May 17, 2026 · Updated 25 times
Summary
This early-phase study tests the safety of a new drug called BIIB145, which is being developed for multiple sclerosis (MS). Since this is the first time the drug is given to people, it involves 104 healthy adults to see how the body handles it and if it causes any side effects. Participants receive either the drug or a placebo in single or multiple doses, with some parts also testing the effect of food. The study does not offer any treatment benefit to participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PPD Austin Clinic
RECRUITINGAustin, Texas, 78744, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.